【AJH】急性髓系白血病的诊断、危险度分层和治疗（2025更新）…
2025年2月18日 · 急性髓系白血病 (AML) 是一种由克隆性造血细胞不受控增殖引起的疾病，占美国所有新发癌症病例的1%。 AML确诊时的年龄一般较高（中位年龄为68岁），5年 OS …
Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a …
1997年9月15日 · Nevertheless, whereas the most common induction therapy for AML consists of 3 days of an anthracycline, usually daunorubicin, and 7 days of cytarabine (3 + 7), many trials …
AML-49 - YouTube
yo, just some average animator whos trying to improve over the months or years or whatever. feel free to sub if you'd like or check out my content if it interests you ig lol also i am the real 49
Emerging agents and regimens for AML - BioMed Central
2021年3月23日 · Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive …
Cytogenetics in the management of acute myeloid leukemia and ...
2023年10月1日 · A large subset of AML (approximately 40%–50% of adult AML and 25% of pediatric AML cases) is cytogenetically normal (CN-AML). Patients with CN-AML are …
针吸细胞学诊断急性白血病皮肤髓外复发临床分析 - PMC
髓外浸润是影响急性白血病预后的重要因素，急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）更容易发生髓外浸润 [1] – [2]，可导致白血病复发或治疗失败。 白血病髓外浸润常表 …
Guidelines Detail - NCCN
- Acute Myeloid Leukemia - Acute Promyelocytic Leukemia - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
指南更新 | 急性髓系白血病NCCN（2025.V1）更新要点一文汇总！ …
aml是成人最常见、最致命的一种急性白血病，临床常用的治疗手段为化疗、靶向治疗和造血干细胞移植等。本次指南更新对不同治疗阶段aml进行了多种方案的新增和调整，进一步促进aml …
神刊发表综述，阐述AML的治疗和研究新进展-MedSci.cn
2024年12月13日 · 影响因子503分的神刊《CA-A Cancer Journal for Clinicians》是美国癌症协会的旗舰期刊，近日发表综述“Acute myeloid leukemia management and research in 2025”，通 …
Antibody–Drug Conjugates for the Treatment of Acute Pediatric …
In acute myeloid leukemia (AML), the CD33 targeting gemtuzumab ozogamicin has demonstrated modest improvements in survival and is the only ADC currently licensed in the United States …
- 某些结果已被删除